Status:
COMPLETED
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal
Lead Sponsor:
PharmaLundensis AB
Conditions:
Chronic Obstructive Lung Disease
Eligibility:
All Genders
45-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study s to determine whether treatment with Iodinated Active Charcoal can improve lung function and physical capacity in patients with chronic obstructive lung disorders. The ratio...
Eligibility Criteria
Inclusion
- Male and \>1 year post-menopausal, or surgically sterile female.
- 45-80 years old.
- Smokers and ex-smokers, at least 15 pack years.
- COPD according to GOLD II. FEV% \< 70 Post beta2-agonist FEV1 \>50 \< 80 % of predicted value
- CO diffusion capacity \< 75 %.
- Active symptomatic COPD with a COPD assessment test (CAT) score \>10.
Exclusion
- Alpha-1 antitrypsin deficiency
- Iodine allergy
- Abnormal thyroid function
- Severely reduced kidney function (Cystatin C \> 1.5 mg/L.
- Exacerbation within 4 weeks prior to the study.
- Use of per oral steroids within 4 weeks prior to the study.
- Alcohol/drug abuse.
- Psychiatric disease.
- Severe cardio-vascular or other severe disease, according to the clinical investigator.
- Oxygen treatment.
- Participation in another ongoing clinical trial or participation in drug
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01404000
Start Date
November 1 2011
End Date
May 1 2013
Last Update
November 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept of Respiratory Medcine & Allergology, Skane University Hospital
Lund, Sweden, 22185